Don’t miss these two opportunities to join us for this educational event, hear the latest updates, interact with experts in the field and earn 1.0 LIVE CME/CPE/CNE credit hour.
Click the button below to register
FINAL LIVE Webinar
Faculty
Loretta J. Nastoupil, MD Catherine S. Diefenbach, MD
Loretta J. Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Houston, Texas
Catherine S. Diefenbach, MD
Associate Professor, Department of Medicine at
NYU Grossman School of Medicine
Director, Hematology Translational Research,
Perlmutter Cancer Center
Director, Clinical Lymphoma Program,
Perlmutter Cancer Center
New York, New York

Program Overview

Although follicular lymphoma (FL) often responds well to initial therapy, many patients will relapse, and a considerable proportion of patients experience disease progression within 24 months. Because of this, managing specific patients with FL remains challenging for clinicians. In this activity, two experts address the recent advances in FL-directed CAR T-cell therapies, bispecific antibodies (BAbs), and antibody-drug conjugates (ADCs). They will discuss safety and efficacy data from ongoing clinical trials, and how to incorporate recently approved and emerging novel targeted therapies into individualized treatment strategies. This program will conclude with a Q&A session. Don’t miss the chance to ask these experts your questions regarding practice.

Agenda

5 minutes Introduction: Changing Practice in Follicular Lymphom
20 minutes CAR T-cell Therapies in F
20 minutes Emerging BAbs and ADCs for FL
5 minutes Application of New Data in Clinical Practice
10 minutes Audience Question & Answer Session

Target Audience
This educational activity is designed for hematology/oncology physicians, advanced practice providers, nurses and pharmacists on the treatment team for patients with follicular lymphoma

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Summarize the latest clinical trial data supporting CAR T-cell therapies for FL
  • Evaluate the latest clinical data and interim results of trials investigating safety and efficacy of BAbs and ADCs in patients with FL
  • Describe practical strategies for individualizing treatment selection in patients with FL
  • Outline strategies for monitoring for, identifying, and mitigating AEs associated with CAR T-cell therapies, BAbs, and ADCs

Accreditation

MediCom Worldwide, Inc. CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-006-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-006-163

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Dr. Loretta Nastoupil has relevant financial relationships related to advisory activities from ADC Therapeutics SA, Bristol-Myers Squibb Company, Caribou Biosciences, Inc., Epizyme, Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology. She has received research grant(s) from Bristol Myers Squibb, Caribou Biosciences, Epizyme, Genentech, IGM Biosciences, Inc., Janssen Pharmaceuticals, Novartis, and Takeda Oncology.

Dr. Catherine Diefenbach has relevant financial relationships related to consulting from Epizyme, Inc., Genmab A/S, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc. She has also received consulting fees and research grant(s) from Bristol Myers Squibb Company, Genentech - A Member of the Roche Group, MorphoSys, and Seattle Genetics, Inc., as well as research grant(s) from Fate Therapeutics.

All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected].
Provided by
MediCom Worldwide, Inc. Supported by an educational grant from Genentech, a member of the Roche Group.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.